{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:44Z","timestamp":1792801904334,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Department of Science and Technology (DECIT); Brazilian Ministry of Health and CNPq","award":["# 40.3293\/2005-7"],"award-info":[{"award-number":["# 40.3293\/2005-7"]}],"id":[{"id":"https:\/\/ror.org\/02y7p0749","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Council for Scientific and Technological Development\/CNPq, Brazil","award":["# 304869\/2008-2"],"award-info":[{"award-number":["# 304869\/2008-2"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"crossref","award":["141554\/2013"],"award-info":[{"award-number":["141554\/2013"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s40249-016-0203-0","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T22:28:07Z","timestamp":1478298487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil"],"prefix":"10.1186","volume":"5","author":[{"given":"Emerith Mayra","family":"Hungria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regiane Morillas","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson Oliveira","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facio Cartaxo","family":"Aderaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Araci de Andrade","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossilene","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heitor de S\u00e1","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L\u00facia Fernandes","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia Regina Franco Sansigolo","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane Martins de Ara\u00fajo","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5984-7770","authenticated-orcid":false,"given":"Samira","family":"B\u00fchrer-S\u00e9kula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,6]]},"reference":[{"issue":"2","key":"203_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1128\/CMR.19.2.338-381.2006","volume":"19","author":"DM Scollard","year":"2006","unstructured":"Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19(2):338\u201381. doi: 10.1128\/CMR.19.2.338-381.2006 .","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"203_CR2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1489\/1544-581X(2004)072<0125:ECOLRY>2.0.CO;2","volume":"72","author":"B Kumar","year":"2004","unstructured":"Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15\u00a0years experience from north India. Int J Lepr Other Mycobact Dis. 2004;72(2):125\u201333.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"12","key":"203_CR3","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1371\/journal.pntd.0001327","volume":"5","author":"DN Lockwood","year":"2011","unstructured":"Lockwood DN, Suneetha L, Sagili KD, Chaduvula MV, Mohammed I, van Brakel W, et al. Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the North Indian INFIR cohort. PLoS Negl Trop Dis. 2011;5(12):e1327.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"203_CR4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.47276\/lr.75.2.143","volume":"75","author":"MI Pimentel","year":"2004","unstructured":"Pimentel MI, Nery JA, Borges E, Goncalves RR, Sarno EN. Impairments in multibacillary leprosy; a study from Brazil. Lepr Rev. 2004;75(2):143\u201352.","journal-title":"Lepr Rev"},{"issue":"2","key":"203_CR5","first-page":"119","volume":"53","author":"JM Pearson","year":"1982","unstructured":"Pearson JM. The evaluation of nerve damage in leprosy. Lepr Rev. 1982;53(2):119\u201330.","journal-title":"Lepr Rev"},{"issue":"3","key":"203_CR6","first-page":"199","volume":"46","author":"JM Pearson","year":"1975","unstructured":"Pearson JM, Ross WF. Nerve involvement in leprosy--pathology, differential diagnosis and principles of management. Lepr Rev. 1975;46(3):199\u2013212.","journal-title":"Lepr Rev"},{"key":"203_CR7","unstructured":"WHO. Chemotherapy of leprosy for control programmes. Geneva; 1982."},{"key":"203_CR8","unstructured":"WHO. A guide to leprosy control. Geneva; 1988."},{"issue":"4","key":"203_CR9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.47276\/lr.85.4.262","volume":"85","author":"ML Penna","year":"2014","unstructured":"Penna ML, Buhrer-Sekula S, Pontes MA, Cruz R, Goncalves Hde S, Penna GO. Results from the clinical trial of uniform multidrug therapy for leprosy patients in Brazil (U-MDT\/CT-BR): decrease in bacteriological index. Lepr Rev. 2014;85(4):262\u20136.","journal-title":"Lepr Rev"},{"issue":"5","key":"203_CR10","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1128\/JCM.41.5.1991-1995.2003","volume":"41","author":"S Buhrer-Sekula","year":"2003","unstructured":"Buhrer-Sekula S, Smits HL, Gussenhoven GC, van Leeuwen J, Amador S, Fujiwara T, et al. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol. 2003;41(5):1991\u20135.","journal-title":"J Clin Microbiol"},{"issue":"4615","key":"203_CR11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.6348948","volume":"221","author":"DB Young","year":"1983","unstructured":"Young DB, Buchanan TM. A serological test for leprosy with a glycolipid specific for Mycobacterium leprae. Science. 1983;221(4615):1057\u20139.","journal-title":"Science"},{"issue":"3","key":"203_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0928-8244(98)00049-2","volume":"21","author":"S Buhrer-Sekula","year":"1998","unstructured":"Buhrer-Sekula S, Cunha MG, Ferreira WA, Klatser PR. The use of whole blood in a dipstick assay for detection of antibodies to Mycobacterium leprae: a field evaluation. FEMS Immunol Med Microbiol. 1998;21(3):197\u2013201.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"4","key":"203_CR13","first-page":"280","volume":"73","author":"L Oskam","year":"2005","unstructured":"Oskam L, Buhrer-Sekula S. A need for clarification of the classification criteria for leprosy patients. Int J Lepr Other Mycobact Dis. 2005;73(4):280\u20131. author reply 1-2.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"8768","key":"203_CR14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/0140-6736(91)91232-J","volume":"338","author":"PW Roche","year":"1991","unstructured":"Roche PW, Theuvenet WJ, Britton WJ. Risk factors for type-1 reactions in borderline leprosy patients. Lancet. 1991;338(8768):654\u20137.","journal-title":"Lancet"},{"issue":"3","key":"203_CR15","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1371\/journal.pntd.0000977","volume":"5","author":"R Jadhav","year":"2011","unstructured":"Jadhav R, Suneetha L, Kamble R, Shinde V, Devi K, Chaduvula MV, et al. Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India. PLoS Negl Trop Dis. 2011;5(3):e977.","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl 2","key":"203_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1590\/S0037-86822008000700014","volume":"41","author":"MFM Brito","year":"2008","unstructured":"Brito MFM, Ximenes RA, Gallo ME, Buhrer-Sekula S. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy. Rev Soc Bras Med Trop. 2008;41 Suppl 2:67\u201372.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"7","key":"203_CR17","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1590\/0074-02760150198","volume":"110","author":"DF Mizoguti","year":"2015","unstructured":"Mizoguti DF, Hungria EMH, Freitas AA, Oliveira RM, Cardoso LPV, Costa MBC, et al. Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1\/LID-1: higher susceptibility to develop type 2 reactions. Mem Inst Oswaldo Cruz. 2015;110(7):914\u201320.","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"3","key":"203_CR18","first-page":"356","volume":"66","author":"MM Stefani","year":"1998","unstructured":"Stefani MM, Martelli CM, Morais-Neto OL, Martelli P, Costa MB, de Andrade AL. Assessment of anti-PGL-I as a prognostic marker of leprosy reaction. Int J Lepr Other Mycobact Dis. 1998;66(3):356\u201364.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"12","key":"203_CR19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/j.1365-3156.2007.01951.x","volume":"12","author":"EA Silva","year":"2007","unstructured":"Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, Das PK, et al. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health. 2007;12(12):1450\u20138.","journal-title":"Trop Med Int Health"},{"issue":"2","key":"203_CR20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2249.2007.03485.x","volume":"150","author":"A Iyer","year":"2007","unstructured":"Iyer A, Hatta M, Usman R, Luiten S, Oskam L, Faber W, et al. Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol. 2007;150(2):210\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"203_CR21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.47276\/lr.79.4.372","volume":"79","author":"SL Walker","year":"2008","unstructured":"Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev. 2008;79(4):372\u201386.","journal-title":"Lepr Rev"},{"issue":"Suppl 1","key":"203_CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1590\/S0074-02762012000900005","volume":"107","author":"GO Penna","year":"2012","unstructured":"Penna GO, Pontes MA, Cruz R, Goncalves Hde S, Penna ML, Buhrer-Sekula S. A clinical trial for uniform multidrug therapy for leprosy patients in Brazil: rationale and design. Mem Inst Oswaldo Cruz. 2012;107 Suppl 1:22\u20137.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"203_CR23","first-page":"125","volume-title":"Action Programme for the elimination of leprosy. Shortening duration of treatment of multibacillary leprosy","author":"WHO","year":"1997","unstructured":"WHO. Action Programme for the elimination of leprosy. Shortening duration of treatment of multibacillary leprosy. Geneva: Weekly Epidemiological Records; 1997. p. 125\u20138."},{"issue":"4","key":"203_CR24","first-page":"253","volume":"67","author":"DN Lockwood","year":"1996","unstructured":"Lockwood DN. The management of erythema nodosum leprosum: current and future options. Lepr Rev. 1996;67(4):253\u20139.","journal-title":"Lepr Rev"},{"key":"203_CR25","unstructured":"WHO. Model Prescribing Information: Drugs Used in Leprosy. Geneva; 1998. p. 1-26."},{"issue":"3","key":"203_CR26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.47276\/lr.83.3.308","volume":"83","author":"ML Penna","year":"2012","unstructured":"Penna ML, Buhrer-Sekula S, Pontes MA, Cruz R, Goncalves Hde S, Penna GO. Primary results of clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT\/CT-BR): reactions frequency in multibacillary patients. Lepr Rev. 2012;83(3):308\u201319.","journal-title":"Lepr Rev"},{"issue":"7","key":"203_CR27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1590\/0074-0276130222","volume":"108","author":"DE Antunes","year":"2013","unstructured":"Antunes DE, Araujo S, Ferreira GP, Cunha AC, Costa AV, Goncalves MA, et al. Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy. Mem Inst Oswaldo Cruz. 2013;108(7):901\u20138. doi: 10.1590\/0074-0276130222 .","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"203_CR28","first-page":"17","volume":"25","author":"ALP Rodrigues","year":"2000","unstructured":"Rodrigues ALP, Rodrigues BF, Pinheirol CA, Borges DS, Mendon\u00e7a MLH, Silva VEF, Goulart IMB. Occurrence of late lepra reaction in leprosy patients: subsidies for implementation of a specific care program. Hansen Int. 2000;25(1):17\u201325.","journal-title":"Hansen Int"},{"issue":"3","key":"203_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.47276\/lr.82.3.213","volume":"82","author":"M Balagon","year":"2011","unstructured":"Balagon M, Saunderson PR, Gelber RH. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24\u00a0months WHO-MDT. Lepr Rev. 2011;82(3):213\u201321.","journal-title":"Lepr Rev"},{"issue":"2","key":"203_CR30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.47276\/lr.83.2.164","volume":"83","author":"J Shen","year":"2012","unstructured":"Shen J, Bathyala N, Kroeger A, Arana B, Pannikar V, Mou H, et al. Bacteriological results and leprosy reactions among MB leprosy patients treated with uniform multidrug therapy in China. Lepr Rev. 2012;83(2):164\u201371.","journal-title":"Lepr Rev"},{"issue":"4","key":"203_CR31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.trstmh.2008.01.004","volume":"102","author":"IP Kahawita","year":"2008","unstructured":"Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg. 2008;102(4):329\u201337.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"203_CR32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1590\/S0037-86822004000500003","volume":"37","author":"JG Guerra","year":"2004","unstructured":"Guerra JG, Penna GO, Castro LC, Martelli CM, Stefani MM, Costa MB. [Erythema nodosum leprosum case series report: clinical profile, immunological basis and treatment implemented in health services]. Rev Soc Bras Med Trop. 2004;37(5):384\u201390.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"203_CR33","first-page":"340","volume":"66","author":"PW Roche","year":"1998","unstructured":"Roche PW, Theuvenet WJ, Le Master JW, Butlin CR. Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone. Int J Lepr Other Mycobact Dis. 1998;66(3):340\u20137.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"3","key":"203_CR34","first-page":"270","volume":"67","author":"R Manandhar","year":"1999","unstructured":"Manandhar R, LeMaster JW, Roche PW. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis. 1999;67(3):270\u20138.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"5","key":"203_CR35","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4269\/ajtmh.2006.74.868","volume":"74","author":"L Pocaterra","year":"2006","unstructured":"Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad. India Am J Trop Med Hyg. 2006;74(5):868\u201379.","journal-title":"India Am J Trop Med Hyg"},{"issue":"4","key":"203_CR36","first-page":"559","volume":"62","author":"DM Scollard","year":"1994","unstructured":"Scollard DM, Smith T, Bhoopat L, Theetranont C, Rangdaeng S, Morens DM. Epidemiologic characteristics of leprosy reactions. Int J Lepr Other Mycobact Dis. 1994;62(4):559\u201367.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"1","key":"203_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1086\/509923","volume":"44","author":"B Ranque","year":"2007","unstructured":"Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, et al. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis. 2007;44(1):33\u201340. doi: 10.1086\/509923 .","journal-title":"Clin Infect Dis"},{"issue":"5","key":"203_CR38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4269\/ajtmh.2007.77.829","volume":"77","author":"AL Sousa","year":"2007","unstructured":"Sousa AL, Stefani MM, Pereira GA, Costa MB, Rebello PF, Gomes MK, et al. Mycobacterium leprae DNA associated with type 1 reactions in single lesion paucibacillary leprosy treated with single dose rifampin, ofloxacin, and minocycline. Am J Trop Med Hyg. 2007;77(5):829\u201333.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"203_CR39","first-page":"211","volume":"53","author":"A Andreoli","year":"1985","unstructured":"Andreoli A, Brett SJ, Draper P, Payne SN, Rook GA. Changes in circulating antibody levels to the major phenolic glycolipid during erythema nodosum leprosum in leprosy patients. Int J Lepr Other Mycobact Dis. 1985;53(2):211\u20137.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"2","key":"203_CR40","first-page":"173","volume":"60","author":"M Becx-Bleumink","year":"1992","unstructured":"Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 1992;60(2):173\u201384.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"2","key":"203_CR41","first-page":"236","volume":"54","author":"G Groenen","year":"1986","unstructured":"Groenen G, Janssens L, Kayembe T, Nollet E, Coussens L, Pattyn SR. Prospective study on the relationship between intensive bactericidal therapy and leprosy reactions. Int J Lepr Other Mycobact Dis. 1986;54(2):236\u201344.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"6","key":"203_CR42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1590\/S0036-46651998000600005","volume":"40","author":"JA Nery","year":"1998","unstructured":"Nery JA, Vieira LM, de Matos HJ, Gallo ME, Sarno EN. Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev Inst Med Trop Sao Paulo. 1998;40(6):363\u201370.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"203_CR43","unstructured":"Brasil. Portaria n\u00b03125 de 07 de outubro de 2010: Diretrizes para vigil\u00e2ncia, aten\u00e7\u00e3o e controle da hansen\u00edase. Bras\u00edlia: Brazilian Ministry of Health - DF2010."},{"issue":"3","key":"203_CR44","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1590\/S0037-86822010000300015","volume":"43","author":"MA Teixeira","year":"2010","unstructured":"Teixeira MA, Silveira VM, Franca ER. Characteristics of leprosy reactions in paucibacillary and multibacillary individuals attended at two reference centers in Recife, Pernambuco. Rev Soc Bras Med Trop. 2010;43(3):287\u201392.","journal-title":"Rev Soc Bras Med Trop"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-016-0203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T11:24:48Z","timestamp":1657625088000},"score":1,"resource":{"primary":{"URL":"http:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-016-0203-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1186\/s40249-016-0203-0","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"110"}}